TriSalus Life Sciences Inc. Cash Flow Conversion Efficiency
TriSalus Life Sciences Inc. cash flow conversion efficiency. Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has a cash flow conversion efficiency ratio of -2.536x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.61 Million) by net assets ($6.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TriSalus Life Sciences Inc. (2021–2025)
Cash flow conversion efficiency of TriSalus Life Sciences Inc. from 2021 to 2025. This chart illustrates how TriSalus Life Sciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View TriSalus Life Sciences Inc. stock price for real-time trading data and today's change.
TriSalus Life Sciences Inc. Cash Flow Conversion Ratio Explained
TriSalus Life Sciences Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TriSalus Life Sciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their cash flow conversion efficiency. Also see TLSI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amtech Systems Inc
NASDAQ:ASYS
|
0.010x |
|
AVE Science & Technology Co Ltd
SHG:688067
|
0.029x |
|
XANO Industri AB (publ)
ST:XANO-B
|
-0.006x |
|
Hold-Key Electric Wire & Cable Co Ltd
TW:1618
|
-0.033x |
|
Precision BioSciences Inc
NASDAQ:DTIL
|
-0.297x |
|
Telecomunicações Brasileiras S.A. - TELEBRÁS
SA:TELB3
|
-0.032x |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
0.117x |
|
Darwin Precisions Corp
TW:6120
|
-0.077x |
Annual Cash Flow Conversion Efficiency for TriSalus Life Sciences Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of TriSalus Life Sciences Inc. from 2021 to 2025. Review TriSalus Life Sciences Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.86 Million | $-18.01 Million | 0.532x | -66.28% |
| 2024-12-31 | $-25.89 Million | $-40.84 Million | 1.577x | -15.60% |
| 2023-12-31 | $-27.07 Million | $-50.58 Million | 1.869x | -28.73% |
| 2022-12-31 | $-12.32 Million | $-32.31 Million | 2.622x | +456.99% |
| 2021-12-31 | $30.90 Million | $-22.70 Million | -0.734x | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more